CompletedNCT00218465
GW468816 compared with placebo to prevent smoking relapse in women
About this title
Read the official source — NCT00218465Medication studyAges 18–65United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Belmont and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateAugust 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 264
- Sponsor
- Massachusetts General Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00218465
- Official title
Show the full official title
A Double-Blind, Placebo-Controlled Trial of the NMDA Glycine Site Antagonist, GW468816, for Prevention of Relapse to Smoking
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Belmont · Boston
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including GW468816 and Placebo Comparator: Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
